As more ALK‐targeted TKIs such as lorlatinib, which is being utilized in neuroblastoma clinical trials currently become available, moving from one ALK‐targeted TKI to another when resistance emerges could become easier similar to multiple‐tiered TKI use in chronic myelogenous leukemia (CML).20, 21. This evidence concerns the gene ALK and neuroblastoma.